GENE ONLINE|News &
Eli Lilly, Lycia Partnership Signifies the Growing Targeted Protein Degradation Market
On August 25th, South San Francisco-based startup Lycia Therapeutics entered a multi-year collaboration with Eli Lilly to discover, develop and commercialize novel targeted therapeutics using the former's proprietary protein degradation technology.
As per the agreement, Lilly will pay Lycia $35 million in an upfront payment. In addition, Lycia is also eligible to receive over $1.6 billion in potential milestone payments as well as tiered royalties from mid-single to low double-digits on sales.
As per the agreement, Lilly will pay Lycia $35 million in an upfront payment. In addition, Lycia is also eligible to receive over $1.6 billion in potential milestone payments as well as tiered royalties from mid-single to low double-digits on sales.
